ABPI responds to the new Innovation Scorecard which shows once again unacceptably wide variation in the uptake of NICE-approved medicines in England
The ABPI has today responded to the latest publication of the NICE Technology Appraisals in the NHS in England - Innovation Scorecard. The Scorecard, published by the Health and Social Care Information Centre (HSCIC), pulls together existing local data from across the NHS to show the regional provision of NICE-approved medicines and technologies.
The ABPI fully supports the Innovation Scorecard in the NHS as a key way of measuring the use of NICE-approved medicines at a local level. It should help promote transparency in the way medicines are used in the NHS. The ABPI would like to see it used more widely across the NHS to medicines use and drive improved planning.
However the ABPI is disappointed that the latest data, covering 83 medicines, continues to show a low use of NICE-approved medicines in the NHS. Compared to expected usage, the use of new medicines in the NHS in England is far lower than expected. The new data also shows that there is still wide regional variation between the medicines that patients can access in some parts of England compared to others. For example, in some cases there is a twenty-fold difference in the use of some medicines between one area team and another.
Alison Clough, Acting CEO of the ABPI, said: "The Scorecard is a key tool in focusing debate on improving patient access to NICE-recommended medicines in England. We welcome its publication and industry fully supports the continued development of metrics. We have worked closely with the Department of Health, HSCIC and other stakeholders to develop the Scorecard and understand the limitations of data that currently exists in the system.
"However it is disappointing, that the new data shows that the use of the latest NICE-recommended medicines in the NHS continues to be unacceptably low. There is a particular issue with the use of medicines in the first five years of their launch. NHS patients are not being allowed access to treatments which could play a significant transformative role in their care and therefore in the outcomes they achieve.
"It is also unacceptable that there is still so much unwarranted variation in the use of new and innovative medicines across England. We strongly believe that all patients should have access to the medicines their clinicians believe they will benefit from, wherever they live.
"We hope that the Government's Accelerated Access Review will address these barriers to patient use and help improve the adoption and diffusion of the newest and most innovative medicines across England."
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
For more information, please contact the ABPI Press Office:Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com